Dr.Monica Avila

We are living beyond✨the era of cytotoxics with a clinical response ceiling 🌦️due to dose-dependent adverse events. We now #live 💫for an independent dose-response curve. Each novel target 🎯 informs a way forward @MoffittNews @MoffittGYNONC

@allisonoconn Of course you are. Nothing creates expertise like experiences!

I saw 6 patients with hairy cell leukemia in one day. There are only 6,000 cases of hairy cell leukemia in the United States! Afterwards I was like… wait…am I the expert now? Jkjk I’m not!

CAR T therapy may be entering its next era. For years, the process has looked the same: 👉 Collect the patient’s T cells 👉 Ship them for manufacturing 👉 Wait weeks for engineering 👉 Give lymphodepleting chemotherapy 👉 Infuse the final product Powerful—but complex, expensive, and time-sensitive. Now, researchers at Winship Cancer Institute of Emory University have administered the first investigational in vivo CAR-T therapy in the United States for relapsed/refractory Multiple myeloma. The concept is remarkable: Instead of engineering CAR T cells outside the body… 👉 engineer them inside the patient. Using KLN-1010, the goal is to generate CAR T cells directly in vivo through targeted lentiviral delivery. No cell collection. No manufacturing delay. Potentially no lymphodepletion. 🧠 If successful, this could fundamentally change the logistics of cellular therapy. The bottleneck may no longer be: “Can we manufacture the cells in time?” But simply: 👉 “Can we deliver the therapy?” Early findings remain preliminary, and many questions remain around: • Safety • Durability • Control of in vivo engineering • Long-term efficacy But conceptually, this is one of the boldest shifts yet in cellular therapy. Congratulations to Drs. Sagar Lonial, Nisha Joseph, Ajay Nooka, and the team at Winship Cancer Institute of Emory University for advancing this next-generation approach. winshipcancer.emory.edu/newsroom/artic…

Really enjoyed the thoughtful interactive lecture 🧠 @andy_andem (@RushMedical) at this year's @USFHealth Program Director's Retreat w/@MoffittNews !Tips for maxing 🧗🏻‍♀️ #clinicalcompetency: milestone mapping🗺️ to visualize redundancy & gaps in #MedEd @acgme

❗ Most gynecologic oncologists recognize #HormoneThreapy can benefit women with #CervicalCancer, but barriers inhibit prescription. ✍️ “We have a solution even if we don’t yet have a pathway,” @MAvilaMD @Moffittnews @MoffittGYNONC vist.ly/54bv6

@MikeWach_MD Congrats friends!

Honored to receive this award and help advance care for patients with Colorectal Peritoneal Metastases!

Cross-specialty 🙌🏼 Collaboration @MoffittNews drives standards 🧮 in #cancercare. Fieldtrip 🚌 to Frozen 🧊 Path Lab w/Dr. Hakam shows how the learner microscope 🔬 teaches premeds 👶🏽, med students 👦🏻 and residents 💁🏻‍♀️ alike, optimizing #surgery results @MoffittGYNONC real-time ⏱️

🧬 #ScienceSaturday ❓ What if cancer treatment could target not only tumor cells, but also the tumor’s stromal support: non-malignant, non-cancerous cells within the tumor microenvironment, that actively help cancer grow, spread, and resist treatment? ➡️ In a new study published in @CellCellPress, researchers identified uPAR, a cell-surface protein linked to aggressive tumor behavior, as a marker found on both solid tumor cells and the fibrotic, immune-suppressive environment that helps sustain them. ➡️ The team developed uPAR-targeted CAR T cells that attacked both tumor cells and their supportive stroma, leading to durable tumor regression across multiple cancer models, including metastatic disease. ➡️ They also found that senescence-inducing therapies, like chemotherapy, increased uPAR expression and made tumors even more vulnerable to CAR T cell treatment. 🌟 This dual-targeting strategy could help overcome some of the biggest barriers to CAR T therapy in solid tumors, including immune suppression and treatment resistance. 🔗 Read the study: cell.com/cell/fulltext/… @ZedaZhang @Aveline_Filliol @LoweLabMSKCC

@DrMarkham speaks with ASCO Connection on working through burnout Beyond the White Coat: Dr. Merry Jennifer Markham on Embracing Your Identity Outside of Medicine | connection.asco.org/do/beyond-whit…

My fav partner in science 🧪🎇 #Georgelab @MoffittNews @MoffittGYNONC

Our wonderful fellow @biancatng1 presenting on temporal #DNA 🧬damage repair (DDR) 🎯pathways🚦in high grade serous #ovariancancer @GOG Fellows Forum under the mentorship of @ErinGeorgeMD #GeorgeLab 🧪🎇@MoffittNews @MoffittGYNONC

Turns out #teamwork 🙌🏼👊🏼👩🏽‍🤝‍👨🏼is what increases productivity 🪡 in the OR. 1) surgeon anesthesia conscious preop time 4 pts🥼 2) presence of OR charge RN checking in on teams 🧏🏻‍♀️ helps #mitigate wasted time 🕐and optimize readiness for the #operatingroom! @SurgJournal @MoffittNews

Thx you @Larvol! @MoffittNews @MoffittGYNONC

#gynoncologists play key 🔑 role in risk reducing surgery #breastcancer pts. New meta-analysis @TheLancet: 60% RR of recurrence in pre-meno pts (particularly <45) w/ ovarian suppression (surgical or therapeutic), risk obviated to 80% RR using tamoxifen @MoffittNews @MoffittGYNONC

#Florida 🌊☀️🍊version of a Sunday #Summit! No mountains, no problem @CityofTampa Courtney Campbell Causeway! #SundayFunday #Hiking #FloridaisFlat #sunshinestate

🚨GIST - New trial alert in Tampa Bay (and FL, in general) - KIT/PDGFRA mutated advanced GIST: StrateGIST-3 trial recruiting at @MoffittNews If you have patients with advanced KIT/PDGFRA-mutated GIST who progressed on or can’t tolerate imatinib, please consider a referral to Moffitt Cancer Center for the StrateGIST-3 trial. This is a 2nd line trial randomizing advanced GIST patients to Velzatinib (IDRX-42) vs. Sunitinib. Fast scheduling + close collaboration with local providers. DM or contact us to learn more.

@KuykendallMd 🤣🤣🤣

You see a histone. I see a macaron.

The MySurgeryRisk model accurately predicts risk of #ICU admission, mechanical ventilation, acute kidney injury, and in-hospital mortality after major surgery, with procedure type and clinician-specific factors as primary predictors. ja.ma/4ejzwXc

New @JAMANetworkOpen, #breast & #prostate ♋️ cancers show ⤵️ mortality: incidence with ⤴️ federal $$$. Could be lead time bias (more dx per $)as both ⏫️ sensitive screening. Perhaps 🤔 , 🕐 to flip this 📊 and focus on suboptimal screening & ⏫️ mortality tumors @MoffittNews